title: Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.
abstract: BACKGROUND
  Allergic rhinitis is a common health problem affecting the immune system. The homeostasis of the immune system is regulated by apoptosis. In this study, serum circulating soluble TRAIL levels of allergic rhinoconjunctivitis patients before and after allergen-specific immunotherapy were evaluated.
  
  
  METHODS
  The sTRAIL levels of pre- and post-treated allergic rhinoconjunctivitis patients (n=25) were compared to age- and sex-matched healthy individuals (n=25). sTRAIL levels were measured by ELISA. The skin prick test (SPT) results were recorded before and after treatment.
  
  
  RESULTS
  The sTRAIL levels between the pre-treated and control groups were significantly different (p<0.0001). However, there was no significant difference between the post-treated group and healthy individuals (p=0,801). SPT was a statistically significant difference between the values of the research group before and after immunotherapy (grasses mixture, barley mixture, Oleaauropeae, D. Pteronyssinus, D. farinae).
  
  
  CONCLUSIONS
  The sTRAIL levels were decreased after allergen-specific immunotherapy to healthy levels and may be of use as a marker of efficacy of immunotherapy in allergic rhinoconjunctivitis patients.
authors.affiliation: Internal Medicine, Allergology and Clinical Immunology Unit, Antalya Education and Research Hospital, Antalya, Turkey. adidyal@yahoo.com
authors.forename: Arzu Didem
authors.initials: AD
authors.lastname: Yalcin
authors.forename: Saadet
authors.initials: S
authors.lastname: Gumuslu
authors.forename: Gizem Esra
authors.initials: GE
authors.lastname: Parlak
authors.forename: Atil
authors.initials: A
authors.lastname: Bısgın
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003231:Conjunctivitis / Q000097:blood* / Q000150:complications / Q000276:immunology / Q000628:therapy*; D003710:Demography; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood* / Q000150:complications / Q000276:immunology / Q000628:therapy*; D012882:Skin Tests; D012995:Solubility; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D053221:TNF-Related Apoptosis-Inducing Ligand